Kripalani Yash, Lakkappan Vidyadhara, Parulekar Lipeeka, Shaikh Anjum, Singh Rakesh, Vyas Pradeep
Department of Critical Care Medicine, Holy Family Hospital, Bandra, Mumbai, India.
Department of General Internal Medicine, Holy Family Hospital, Bandra, Mumbai, India.
Eur J Case Rep Intern Med. 2021 Sep 14;8(9):002707. doi: 10.12890/2021_002797. eCollection 2021.
Various vaccines against COVID-19 have been developed since SARS-CoV-2 emerged at the end of 2019. Their emergency administration in healthcare settings has been accompanied by numerous adverse effects. A case of Guillain-Barré syndrome following vaccination with Covishield is presented here to highlight this possible adverse condition.
Guillain-Barré Syndrome (GBS) is a very rare complication after vaccination against SARS-CoV-2.The key concepts related to the understanding, management and outcomes of patients with GBS are discussed.
自2019年底严重急性呼吸综合征冠状病毒2(SARS-CoV-2)出现以来,已研发出多种针对2019冠状病毒病(COVID-19)的疫苗。这些疫苗在医疗机构中的紧急接种伴随着众多不良反应。本文介绍了1例接种科维希尔德(Covishield)疫苗后发生吉兰-巴雷综合征的病例,以突出这种可能的不良状况。
吉兰-巴雷综合征(GBS)是接种抗SARS-CoV-2疫苗后非常罕见的并发症。文中讨论了与GBS患者的理解、管理和结局相关的关键概念。